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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comUpon univariate analyses, baseline ofﬁce systolic BP (p< 0.0001) and BMI (p¼0.014)
were identiﬁed as signiﬁcant predictors of a BP response after 6 months. Obese pa-
tients with a BMI of 30.0 had a signiﬁcantly lower BP response after 6 months
(-8.9  18.8 mmHg) compared to normal-weight patients with a BMI  29.9 (-20.1 
24.9 mmHg; p¼0.013). Importantly, stepwise backward regression model revealed
baseline ofﬁce systolic BP (standardized ß¼-0.46; r¼-0.47; p< 0.0001) and BMI
(standardized ß¼0.21; r¼0.95; p¼0.019) as signiﬁcant variables for BP response after
6 months. The other variables remained insigniﬁcant.
Conclusions: Hypertension severity and BMI are important predictors of BP response
to RDN. BP reduction after RDN is, in fact, more pronounced in patients with lower
BMIs. These ﬁndings may help in patient selection.
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Background: Percutaenous renal artery denervation has been shown to decrease
blood pressure among patients with resistant arterial hypertension. We present in this
review a meta-analysis of all randomized controlled trials evaluating effectiveness and
complications of catheter-based RDN for blood pressure control in patients with
resistant hypertension.
Methods: Pub Med, Chocrane and Scopus were systematically searched up to May
2014. Primary outcomes were 6 months reduction of ofﬁce systolic and diastolic blood
pressure. Secondary outcomes were 24 hours systolic blood pressure reduction, more
than 10mmHg systolic blood pressure reduction and MACE (death, stroke/TIA, and
AMI). We used Fixed or Random Effect analysis using the Cochrane Handbook of
Systematic Reviews.
Results: 3 RCTs provided a total of 651 patients; 415 inthe RDN groupd and 236 in
the control. Ofﬁce systolic blood pressure decrease of 18.29 mmHg and 6.83 mmHg
mean diastolic reduction(for both p < 0.05). A strong trend in the 24-hours systolic
blood pressure mean reduction -10.99 at 6 months and signiﬁcantly more patients
responded to the RDN therapy presenting with  10 mmHg systolic blood pressure
decrease (for both p ¼0.05) without any MACE.Conclusions: Resistant hypertension treated with catheter-based RDN respond
better to blood pressure reduction and with sustained control without carrying
signiﬁcant kidney and cardiovascular complications. It is yet to be determined if
some RDN catheters are capable to provide more concise results and therefore lead
to better procedural outcomes. Therefore more randomized clinical data are
warranted.B122 JACC Vol 64/11/Suppl B j September 13–17, 2014TCT-416
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Background: Renal denervation interrupts the sympathetic pathways to the kidneys
and therefore may decrease blood pressure. This technique is increasingly being
evaluated for the management of resistant hypertension.
Methods: All the available electronic databases were queried for studies on renal
denervation for resistant hypertension. Studies that had a minimum follow up period
of 6 months were included. Meta-analysis of the weighted mean difference of pre and
post renal denervation blood pressures was performed using random effects model.
Results: A total of 18 studies met our inclusion and exclusion criteria and were
included in the ﬁnal analysis. Ofﬁce blood pressures were reported in 16 studies, while
ambulatory blood pressures were reported in 7 studies. At 6 months, post renal
denervation, the ofﬁce systolic blood pressure decreased by 25.2 mm Hg (95% CI,
24.7 – 25.7 mm Hg). Ofﬁce diastolic blood pressure was lowered by 9.6 mm Hg (95%
CI, 8.1 – 11 mm Hg). The ambulatory systolic and diastolic blood pressures also
decreased by 12 mm Hg (95% CI, 4.4 – 19.7 mm Hg) and 6.5 mm Hg (95% CI, 3.3 –
9.5 mm Hg), respectively. At 1 year after renal denervation, the ofﬁce systolic blood
pressure was lowered by 24.6 mm Hg (95% CI, 21.9 – 27.4 mm Hg). The ofﬁce
diastolic blood pressure was decreased by 10.7 mm Hg (95% CI, 8.4 – 12.9 mm Hg) at
1 year follow up.Conclusions: Renal denervation effectively lowers both systolic and diastolic blood
pressures in subjects with resistant hypertension. The blood pressure lowering effect
appeared to be sustained at 1 year after renal denervation.
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Background: The Paradise Renal Denervation System (ReCor Medical, Palo Alto,
CA) delivers ultrasound (US) energy to perform circumferential denervation of the
renal sympathetic nerves. The REALISE trial is a French post-market study in
moderate resistant hypertensive (RH) patients with active hypertension medication
management. Six-month safety and effectiveness data will be presented, as will
MSNA data collected in a subset of patients to evaluate the ability of US denervation
to down-regulate sympathetic activity.
Methods: The REALISE trial is a prospective, single-arm, open-label study. The
study enrolled patients with ofﬁce BP >140/90, conﬁrmed by ambulatory measures,
and on a minimum of 3 medications. Patients were treated with up to 3 US emissions
bilaterally. All patients underwent CT-scan or MRI at baseline and follow-up to assess
the renal arteries. Ofﬁce and ambulatory BP measures and changes in medications
were recorded at regular intervals. MSNA was obtained in ﬁve patients at baseline and
post procedure.j TCT Abstracts/Hypertension Therapies Including Renal Denervation
